Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Ulcerative Colitis · Multiple Myeloma

AbbVie Deutschland GmbH

AbbVie Deutschland GmbH & Co. KG

AbbVie Deutschland GmbH clinical programs — 102 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Wiesbaden, DE HQ
2018 Founded
101 Employees
EMA registrant Type
Company details
Status
Public
HQ
Wiesbaden, DE
Founded
2018
Employees
101
Programs
102
Drugs
119
Patents
23
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

AbbVie Deutschland GmbH projects

102 ClinicalTrials.gov programs sponsored by AbbVie Deutschland GmbH.

AbbVie Deutschland GmbH has 102 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

102 programs

Clinical programs

Page 2 of 3

  1. IMGN632-0802

    AbbVie Deutschland GmbH & Co. KG

    CD123 positive Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  2. IMGN853-0424

    AbbVie Deutschland GmbH & Co. KG

    Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

    phase 2 small molecule active

    1 trial

  3. M15-654

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  4. M16-109

    AbbVie Deutschland GmbH & Co. KG

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  5. M19-965

    AbbVie Deutschland GmbH & Co. KG

    HIV infection

    phase 2 small molecule active

    1 trial

  6. M22-132

    AbbVie Deutschland GmbH & Co. KG

    B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  7. M23-422

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    phase 2 small molecule active

    1 trial

  8. M23-703

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  9. M24-147

    AbbVie Deutschland GmbH & Co. KG

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  10. M24-209

    AbbVie Deutschland GmbH & Co. KG

    Light Chain Amyloidosis

    phase 2 other active

    1 trial

  11. M24-311

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  12. M24-533

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  13. M24-536

    AbbVie Deutschland GmbH & Co. KG

    Advanced or Metastatic Non-Squamous NSCLC

    phase 2 small molecule active

    1 trial

  14. M24-555

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  15. M24-633

    AbbVie Deutschland GmbH & Co. KG

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. M24-885

    AbbVie Deutschland GmbH & Co. KG

    Moderate to Severe Crohn’s Disease

    phase 2 small molecule active

    1 trial

  17. M24-977

    AbbVie Deutschland GmbH & Co. KG

    Adenocarcinoma of the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  18. M25-056

    AbbVie Deutschland GmbH & Co. KG

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  19. M25-059

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  20. M25-204

    AbbVie Deutschland GmbH & Co. KG

    Urothelial Carcinoma, Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  21. M25-275

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma (MM).

    phase 2 small molecule active

    1 trial

  22. M25-709

    AbbVie Deutschland GmbH & Co. KG

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  23. MEDI0618, Placebo to match MEDI0618

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 2 small molecule active

    1 trial

  24. PCYC-1146-IM

    AbbVie Deutschland GmbH & Co. KG

    Chronic Graft Versus Host Disease (cGVHD)

    phase 2 small molecule active

    1 trial

  25. PIVEKIMAB SUNIRINE

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia and other blood cancers

    phase 2 small molecule active

    1 trial

  26. Placebo for ABBV-142

    AbbVie Deutschland GmbH & Co. KG

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  27. Telisotuzumab Vedotin

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  28. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene

    phase 2 small molecule active

    1 trial

  29. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  30. Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease (CD)

    phase 2 small molecule active

    1 trial

  31. Livmoniplimab, Budigalimab

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumors, Solid Tumors

    phase 1 small molecule active

    1 trial

  32. M15-531

    AbbVie Deutschland GmbH & Co. KG

    Myelodysplastic Syndromes (MDS)

    phase 1 other active

    1 trial

  33. M16-573

    AbbVie Deutschland GmbH & Co. KG

    Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer

    phase 1 other active

    1 trial

  34. M19-753

    AbbVie Deutschland GmbH & Co. KG

    Myelofibrosis, Myeloproliferative Neoplasms

    phase 1 small molecule active

    1 trial

  35. M20-258

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 1 other active

    1 trial

  36. M21-404

    AbbVie Deutschland GmbH & Co. KG

    Advanced solid tumors including (but not limited to), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric/gastroesophageal junction adenocarcinoma (GEA), colorectal cancer (CRC), and renal cell carcinoma (RCC)

    phase 1 other active

    1 trial

  37. M22-716

    AbbVie Deutschland GmbH & Co. KG

    Follicular lymphoma (FL), Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), B-cell malignancies

    phase 1 other active

    1 trial

  38. M22-947

    AbbVie Deutschland GmbH & Co. KG

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  39. M23-001

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Multiple Myeloma (R/R MM)

    phase 1 other active

    1 trial

  40. M23-385

    AbbVie Deutschland GmbH & Co. KG

    Advanced solid tumors

    phase 1 other active

    1 trial

  41. M23-647

    AbbVie Deutschland GmbH & Co. KG

    Select B-Cell malignancies.

    phase 1 other active

    1 trial

  42. M24-291

    AbbVie Deutschland GmbH & Co. KG

    Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia

    phase 1 other active

    1 trial

  43. M24-427

    AbbVie Deutschland GmbH & Co. KG

    locally advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  44. M24-742

    AbbVie Deutschland GmbH & Co. KG

    Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  45. M24-893

    AbbVie Deutschland GmbH & Co. KG

    Non-Hodgkin's Lymphoma

    phase 1 other active

    1 trial

  46. M25-292

    AbbVie Deutschland GmbH & Co. KG

    Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Cancer

    phase 1 other active

    1 trial

  47. M25-433

    AbbVie Deutschland GmbH & Co. KG

    Systemic Lupus Erythematosus, Sjogren's disease

    phase 1 other active

    1 trial

  48. Mass Balance Study of [14C] ABBV-932 in Healthy Male Volunteers

    AbbVie Deutschland GmbH & Co. KG

    Healthy Volunteers

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does AbbVie Deutschland GmbH have?

102 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.